AMENDMENT TO THE CONTENT OF PRICE INQUIRY NO. SEMA/33/PR52982-56041/2024 UPDATE 10.04.2024.

Subject: Project titled . "*Design and development of an innovative solution - a drug from the group of GLP-1 receptor agonists in the treatment of type 2 diabetes*" funded by the state budget from the Agency for Medical Research, Zakłady Farmaceutyczne Polpharma S.A.,

Subject of purchase - provision of service related to the development and supply of reusable injector pens.

The ordering party informs that on 15.04.2024 revised the content of the price inquiry to the following extent:

Description before change	Description after the change
VI. METHOD OF PRICE CALCULATION	
 VI.1 How to calculate the bid price: the price should be calculated net. VI.2 For evaluation, bids submitted in a currency other than PLN will be converted into PLN at the average exchange rate of the National Bank of Poland (https://www.nbp.pl/) on the closing date for submission of bids. VI.3 The price should include all costs associated with the preparation and execution of the subject of the request. VI.4 The price submitted in the bid cannot be changed during the execution of the contract. 	 VI.1 How to calculate the bid price: the price should be calculated net. VI.2 For evaluation, bids submitted in a currency other than PLN will be converted into PLN at the average exchange rate of the National Bank of Poland (https://www.nbp.pl/) on the closing date for submission of bids. VI.3 The price should include all costs associated with the preparation and execution of the subject of the request. VI.4 The price submitted in the bid cannot be changed during the execution of the contract. VI.5 If the supplier's income earned in connection with the execution of the project is subject to
	withholding tax in Poland, then Zakłady Farmaceutyczne Polpharma S.A. is required by law to withhold withholding tax from the supplier's remuneration and pay it to the Polish tax authorities (the remuneration includes withholding tax).